Keyphrases
Non-small Cell Lung Cancer (NSCLC)
77%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
56%
Lung Cancer
41%
Overall Survival
41%
Tumor
28%
Non-small Cell Lung Cancer Patients
27%
Immune Checkpoint Inhibitors
25%
Chemotherapy
21%
Lung Cancer Patients
19%
Confidence Interval
17%
Pembrolizumab
17%
Cancer Cells
17%
Durvalumab
15%
Small Cell Lung Cancer
15%
Progression-free Survival
13%
Nivolumab
13%
Platinum-based Chemotherapy
13%
Median Overall Survival
12%
Hazard Ratio
12%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
11%
Tyrosine Kinase Inhibitor
11%
Cancer Patients
11%
EGFR mutation
11%
Tumor Cells
11%
In Cancer
10%
Israel
10%
Retrospective Analysis
10%
Osimertinib
10%
Programmed Death-ligand 1 (PD-L1)
9%
Adverse Events
9%
Adenocarcinoma
9%
Interferon-α (IFN-α)
9%
Epidermal Growth Factor Receptor
9%
Objective Response Rate
9%
Metastatic Disease
9%
Immunohistochemistry
8%
Predictive Biomarker
8%
Clinical Trials
8%
Early-stage Lung Cancer
8%
DNA Damage
8%
Cisplatin
8%
Multivariate Analysis
7%
Stromal Cells
7%
Erlotinib
7%
Melanoma Patients
7%
Phase I Study
6%
Median Progression-free Survival
6%
Monotherapy
6%
Phase II Trial
6%
Real-life Cohort
6%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
52%
Neoplasm
38%
Overall Survival
38%
Epidermal Growth Factor Receptor
33%
Malignant Neoplasm
25%
Immune Checkpoint Inhibitor
21%
Progression Free Survival
19%
Small Cell Lung Cancer
18%
Disease
17%
Chemoradiotherapy
17%
Tyrosine-Kinase Inhibitor
17%
Immunotherapy
16%
Durvalumab
15%
Adenocarcinoma
15%
Non-Small Cell Lung Cancer
14%
Radiation Therapy
13%
Metastatic Carcinoma
13%
Nivolumab
13%
Hazard Ratio
13%
Clinical Trial
12%
Tumor Cell
12%
Adverse Event
11%
Biological Marker
10%
Cancer Cell
10%
Exon
10%
Pembrolizumab
10%
Protein P53
7%
Smoking
7%
Cisplatin
7%
Immunohistochemistry
7%
Fibroblast
7%
Nodular Melanoma
6%
Breast Cancer
6%
Osimertinib
6%
Programmed Death-Ligand 1
6%
Long Term Survival
6%
Erlotinib
6%
COVID-19
6%
Liquid Biopsy
6%
Colorectal Cancer
6%
Interferon
6%
Cell Invasion
6%
Electrocorticography
6%
Biopsy
6%
Angiogenesis
5%
Brain Metastasis
5%
Surgery
5%
Retrospective Study
5%
Breathing
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
82%
Lung Cancer
50%
Overall Survival
41%
Chemotherapy
37%
Neoplasm
35%
Malignant Neoplasm
35%
Epidermal Growth Factor Receptor
30%
Progression Free Survival
24%
Disease
22%
Protein Tyrosine Kinase Inhibitor
19%
Durvalumab
19%
Small Cell Lung Cancer
17%
Pembrolizumab
17%
Protein P53
15%
Chemoradiation Therapy
15%
Immune Checkpoint Inhibitor
15%
Adverse Event
14%
Immunotherapy
12%
Biological Marker
11%
Cisplatin
10%
Nivolumab
10%
Clinical Trial
10%
Osimertinib
9%
Erlotinib
9%
Colorectal Cancer
9%
Adenocarcinoma
9%
Metastasis
7%
Long Term Survival
6%
Cediranib
6%
Veliparib
6%
Recurrent Disease
6%
Coronavirinae
6%
Lactate Dehydrogenase
6%
Interferon
6%
Crizotinib
5%
Brain Metastasis
5%
microRNA
5%
Carboplatin
5%
Solid Malignant Neoplasm
5%
